Introduction
For most patients with end-stage heart failure (more than 90%) there is no definitive treatment option up to now. This fact is caused on the one hand by a severe shortage in donor hearts, and on the other hand by technical and economic limitations of mechanical cardiac assist devices and artificial hearts. An additional cardiac output of 2-3 litres per minute should give most patients with end-stage heart failure a better quality of life and a longer survival. Latissimus dorsi muscle as a source for muscular blood pumps would have several advantages. Its availability is nearly unlimited, there is no foreign tissue rejection and of course no need for an immune-suppression, less risk of infection and this procedure should be less costly than heart transplantation and the treatment with fully implantable cardiac assist devices and artificial hearts.
Skeletal muscle ventricles (SMVs) and Biomechanical Hearts (BMHs) are experimental muscular blood pumps to support the circulation. They are developed and tested as future treatment option for patients with end stage heart failure. SMVs and BMHs basically have two main limitations: firstly muscle damage after electrical muscle fiber transformation from a fast twitched into a slow twitched non-fatigue muscle and secondly thromboembolic complications from the blood contacting surface especially when a muscular blood pump works on demand. Former investigators developed sack-ventricles within circulation in dogs pumping up to 4 years [1] [2] [3] [4] [5] . 
Training device
To study muscle protection of LDM under different stimulation patterns and drugs to improve muscular power an elastic training device was created, where the LDM was wrapped around and muscle performance could become evaluated [6] .
The training device ( Figure 3 ) is made of silicone rubber (Q3, Dow Corning). It consists of a central chamber and two compliant side bladders filled with saline solution. The barrel-shaped central chamber and the side bladders have volumes of 150 mL and 50 mL each, respectively. The side bladders are constructed with a compliance of 1.0 to 1.3 mL/mmHg, simulating the windkessel characteristics of the arterial system in normal subjects with 1.07 mL/mmHg. More technical details can be found elsewhere (Guldner et al.,1994; . 
Intra-thoracic implantation
Experiments were carried out in adult Boer goats (Figure 1) , with a weight of 70±11 kg. They were castrated 4 weeks before the operation to keep them together and avoid injuries between them. The experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health. They were supervised by a representative of the District President of the local society for Prevention of Cruelty to Animals.
The operation was performed under general anaesthesia. Left LDM was dissected free, folded to a double layer, and wrapped around the central chamber of the training device. The SMV was transferred into the thorax and fixed at the thoracic wall.
Commercially available myostimulators were used (Medtronic model 7420/7424 and Telectronics model 7220). An epi-mysial electrode 30mm long (custom-made, Medtronics, Bakken Research Center) was attached to the muscle close to the branches of the nervus thoracodorsalis. On the opposite side of the muscle, an electrode 60mm long (Medtronics SP 5591 -500-60-NMS) was placed sub-fascially. Method of stroke volume and stroke energy determination, relating pressure increase of a ventricle contraction (left) to the compliance curve of the bladders of the Frog, stroke volume is received (right). The area of the stroke volume below the compliance curve represents the stroke work or stroke energy [7] .
Stroke volume evaluation is performed relating maximal pressure P max from the pressure curve during muscle contraction to the compliance curve of the Frog's elastic side bladders ( Figure  5 ). Stroke volume multiplied with P max results in stroke work W. Daily energy in KJ/d is to calculate by stroke work W multiplied with the number of SMV contractions per day.
Clenbuterol supported dynamic training of skeletal muscle ventricles against systemic load
The profound loss of power that occurs in skeletal muscle after electrical conditioning has been the major limiting factor in its clinical application. This study investigates a 3-fold approach for chronic conditioning of skeletal muscle ventricles combining electrical transformation, dynamic training against systemic load and pharmacological support with clenbuterol.
In 10 adult male goats, SMVs were constructed from latissimus dorsi wrapped around an intrathoracic training device with windkessel characteristics [8] . SMVs were stimulated electrically and trained dynamically by shifting volume against systemic load. Group 1 goats were controls (n=5), and group 2 goats (n=5) were supported with clenbuterol (150µg 3 times a week).
Peak pressure, stroke volume and stroke work per day were significantly improved (p< 0.007) in the clebuterol-treated group after 151±2.7 days ( Fig. 6 ). At termination, myosin heavy chains were totally transformed into myosin heavy chain-I in all SMVs. Other investigators found different functional and histological effects of clenbuterol in dogs [9] . 
Fibertransformation preserving non-fatiguable Typ IIa fibers
In our experience muscular blood pumps that were active over several months, were highly vulnerable when totally transformed into type I muscle showing severe muscle damage and decreased function. Thus, in our new experimental setting, encouraged by the Liverpool findings of the working group of Salmons and Jarvis [10] , fast and fatigue resistant muscle ventricles were performed around the Frog. Pre-stimulation with about 2 Hz proceeded in situ, to open intramuscular collaterals connecting the proximal with the distal blood supply of the muscle and to increase capillary density. Thereafter we used continuous basic burst stimulation with an average pulses frequency of less than 1 Hz. Intermittent series of pumping within the Frog were performed, measuring pumping capacity in correlation to stimulation frequency. This procedure should be a "model setting" for a pumping on demand. During our first investigations, we could see that intermittent pumping capacity was already manifold after 4 to 5 months of pumping ( Figure 8 ). . Figure 10 . Gel electrophoresis of myosin heavy chains MHC I and MHC IIa from group A with a mean pulse frequency of 5 Hz. Control (C) was the non stimulated contra-lateral LDM. In group B with a mean stimulation frequency of 1 Hz, type IIa MHC is well preserved and about 50% after several months in all stimulated SMVs.
Stroke volume of SMVs with 100% type-I-fiber (A) vs. SMVs with 50% type-IIa fiber (B)
As an example one fast, relatively fatigue resistant SMV delivered a maximal pump volume of about 3 L/min. It could be maintained over two minutes. Thereafter it decreased to 1,5 L/min after 5 minutes. This dynamic adaptation of stroke volume per minute in that high level of pumping volume up to 3 L/min was solely possible in the 50% type IIa fibre muscle. 100 % type I fibre ventricles did enhance its pumping capacity however only up to 1 L/min. These recent experimental results in SMVs around the Frog were basic to construct a preclinical Biomechanical Heart Model on demand, which is described as follows.
Valve-less Biomechanical Hearts
Biomechanical Hearts, constructed in adult Boer goats (n=5), are blood pumps, consisting of a pumping chamber with clinically relevant stroke volumes [11] . They can be integrated into the circulation in a one-step operative procedure during pharmacological stimulation with the β-2-stimulator Clenbuterol (5 x150µg/wk). This experimental pumping chamber, made of PTFE, was anastomosed to the descending aorta by two ring armoured PTFE-prostheses (Impra Medica GmbH, München), as shown in Figure 13 . The pumping chamber was used mainly for three reasons: firstly, to stabilize the ventricular pump cavity with improved flow characteristics to minimize thrombo-embolic complications; secondly, to prevent muscle damage by overstretch-induced ischemia; and thirdly, to prevent a ventricular chamber rupture.
During surgery, the mean stroke volume of BMHs was 53.8±22.4 ml. One month after surgery, in peripheral pressure, the mean and minimal diastolic pressure of BMH-supported heart cycle differed significantly from unsupported ones ( Figure 14) . After BMHsupported heart contractions, the subsequent maximal rate of pressure generation, dP/dt max increased by 20.5±8.1% (p<0.02). One BMH, catheterized 132 days after surgery, shifted a volume of 34.8 mL per beat and 1.4 L/min with a latissimus dorsi muscle of 330 g ( Figure  14 , top). 
Hemodynamic evaluations of a valve equipped Biomechanic Heart Model supporting a failing myocardium in goats
As shown previously in goats, valve-less Biomechanical Hearts (BMHs) of a clinically relevant size could be trained effectively in the systemic circulation under support of clenbuterol.
Pumping capacity was more than 1 L/min but due to a high pendulum volume no significant flow contribution for the circulation was gained. Thus, the following investigations were performed to evaluate the efficacy of valve-equipped BMHs in comparison to valve-less BMHs.
To mimic the clinical situation, this test was performed in failing hearts [12] .
Heart failure was induced in adult Boer goats (n=5) by a repeated intra-coronary embolization. A valve-bearing and balloon-equipped pumping chamber was integrated into the descending aorta simulating standardized circulatory BMH support. Circulatory flow was evaluated by a flow meter around the pulmonary artery. Myocardial function was evaluated by a conductance catheter placed in the left heart ventricle (Figure 16 ). Figure 16 . BMH model is made of a stiff polyurethane chamber with an integrated pumping balloon. The dividing and re-uniting vascular prostheses were connected end -to-end with the divided descending aorta. In this setting two of the four prosthetic limbs carried heart valves. Thus, by clamping, no, one or two valves could be integrated into the circulation. The influence of different valve configurations on circulation could be evaluated in supporting a failing heart. Ultrasonic flow probes were placed around the pulmonary artery, aortic arch and the descending aorta. Within the left heart ventricle a conductance catheter was placed, and via a catheter within the left coronary artery an embolization could be induced and a flow wire could be introduced [12] .
Figure 17.
Results of the BMH model described in Fig. 16 , without, with a distal and with two valves: mean aortic pressure( P Ao , grey column), mean pulmonary flow (Q PA , black column), mean flow velocity within the left coronary artery (V C , white column) [12] .
Skeletal Muscle Ventricles (SMVs) and Biomechanical Hearts (BMHs) with a Self Endothelializing Titanized… http://dx.doi.org/10.5772/55993 355 Valve-less BMHs offered an additional pulmonary flow of 113± 37 ml/min resp. 5.4±1.8%, those with one distal valve offered 304±126 ml/min resp. 14.5±6%. BMHs equipped with two valves increased the pulmonary blood flow by 1235± 526 ml/min resp. 58±25 % (p<0.05), the mean aortic pressure in this setting raised to 19±9 mmHg (p<0.05) and the coronary flow velocity to 59±18 mm/sec (p<0.05). Corresponding reduction of left ventricle's end-diastolic pressure ranged from 31 to 17 mmHg (p<0.05), while the myocardial dp/dt increased by 470±192 mmHg/ s resp. 145±48 % (p<0.05). The use of two valves in BMHs is essential for a relevant circulatory support. Unloading and contractility of the left heart ventricle were thus improved significantly. Two-valves-BMHs driven by a sufficient skeletal muscle ventricle may contribute to the therapy of a failing myocardium. Figure 19 . Reduction of the left ventricular end-diastolic pressure (LVEDP, black columns) evaluated as demonstrated in Figure 16 and 18 and an increase of the left ventricular contractility activation of the pumping balloon from the BMH-model in Figure 16 , without, with a distal and with a proximal and a distal valve.
Valve equipped Biomechanical Hearts
As demonstrated above, efficacy of BMHs on the circulation is dependent on the integration of two heart valve prostheses into the in-and outflow part of the pumping chamber. Valve equipped Biomechanical Hearts were constructed and integrated within circulation in adult Boer goat (n=5), and pharmacological stimulation with the β-2-stimulator Clenbuterol.
(5X150µg/wk). This pumping chamber, made of PTFE, was anastomosed to the descending aorta by two ring armoured PTFE-prostheses (Impra Medica GmbH, München). Between these prostheses two porcine glutaraldehyde fixed valve bearing porcine aortic conduits were integrated like shown in Figure 20 . 
Self-endothelializing titanized blood contacting surface for Biomechanical Hearts
Titanium has proven itself as the leading structured metallic biomaterial for 50 years [13] . One reason for this widespread use is the excellent biocompatibility of the metal and its alloys [14] . Theoretically, surface coating of the blood contacting PTFE may open new avenues for improving biocompatibility of this kind of implant material. However, a titanium coating on PTFE seemed not to be possible until now due to the high temperatures needed for commonly used sputtering techniques. Therefore a novel coating method was used [15] for PTFE applying a plasma activated chemical gas deposition (PACVD) at temperatures of 30-35°C. PACVD is a coating technology (Pfm Titanium GmbH, Nürnberg, Germany, patent number EP 0 897 997 A1) where the so called precursor (Tetrakisdimethylamidotitanium, Ti [N(CH 3 ) 2 ] 4 ) is transferred into the gas phase and brought into the reactor by a carrier gas like nitrogen gas [16] . The plasma is able to supply the substrate with high energy while the temperature during deposition can be kept low at about 30-35°C. Within that non-thermal plasma with high electron temperatures but neutrons and ions at room temperature, solely the electrons can follow a quickly changing electrical field with a typical frequency of 13.56 MHz under low pressure plasma as described in detail elsewhere [17] . The precursor, or part of it, reacts with the substrate and creates a layer of 30nm in thickness ( Figure 23) .
Groups by plasma ernergy
The blood contacting surface of the PTFE-made pumping chamber was titanized as described above. This titan surface attracts progenitor cells derived from the bone marrow which were delivered into circulation. The seeded cells transform into endothelial cells within time [18] . This kind of self-tissue engineering of the blood contacting surface is mandatory to prevent thrombo-embolism mainly for blood pumps contracting on demand [14] . 
Summary and perspectives
A BMH is therapeutically indicated for patients with end-stage heart failure with an additional need of a support with 2-3 litres per minute "on demand", especially for candidates older than 60 years having no chance for heart transplantation. For a severe bi-ventricular myocardial insufficiency however, heart transplantation is the first choice.
Experimental Biomechanical Hearts in Boer goats with autologous skeletal muscle were to construct pumping up to 1.400 mL/min for more than 400 days under support of Clenbuterol. Furthermore was to demonstrate that a BMH model supporting a failing heart in Boer goats could pump about 2 litre blood per minute additionally. BMHs equipped with two valves were most effective in-vivo. Effective circulatory support by counter pulsation was achieved by SMVs elsewhere [19] .
Muscle damage and power-loss of a BMH can be avoided by a muscle protective myostimulator applying a closed-loop controlled stimulation and thus maintaining type IIa fibres over years (Microstim GmbH, MyoSen®, Wismar; Germany). A titanized blood contacting surface with endothelialization (Pfm titanium GmbH, Nürnberg; Germany) might prevent thromboembolic complications. In the light of 25 years of systematic progress in basic science of muscle powered cardiac assist this biologic treatment option should become reconsidered as a future surgical treatment option for the therapy of end-stage heart failure [20] .
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